Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma China Annual Forum 2017

March 23, 2017 | China, Events, Patient journey, Pei Li Teh, Pharma China Annual Forum, emerging markets 

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00. 

The patient is an important stakeholder in the treatment of chronic conditions in urban China. Patients, as well as their family members, play an important role in determining their own treatment. They decide when to present, they choose the hospital, many pay out of their own pocket for treatments and they are perhaps the key determinant in the duration of therapy. Therefore it is essential  to understand how the patient journey is evolving and the extent to which this will impact the pharmaceutical industry in the next 5 years. 

This paper will outline the universal truths of the chronic disease patient journey in China, as well as the key inflection points that have the biggest impact on treatment outcomes. Finally, by exploring the distinct healthcare challenges that China looks set to face, Pei Li will discuss the potential for pharma to address these challenges using a series of detailed case studies. 

Throughout the event Pei Li will be on hand to answer any questions you might have regarding our expertise and experience in emerging markets. If you are planning to attend the Pharma China Annual Forum and would like to meet with Pei Li, or are unable to attend but would be interested in receiving a copy of the paper please feel free to contact us.

Research Partnership is committed to staying at the cutting edge of healthcare research in emerging markets. As well as attending relevant conferences and exhibitions we are also regular speakers at relevant forums.

Find out more: http://bit.ly/2mXl6PY

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

20 questions: Round 1

As it's our 20th year anniversary, we invited our employees to play 20 questions - this month "What's the biggest challenge you've overcome at Research Partnership?"Watch the video: https://www.researchpartnership.com/news/2017/03/20-questions-round-1/

Brand tracking research

A common challenge for brand tracking is ensuring the research programme stays relevant to the brand’s current environment. In this video Quantitative Research Directors Karen Swords and Vicky McLellan outline...

Pharma China Annual Forum 2017

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Healthcare Market Research in the Gulf: 3 lessons I’ve learned

A few key considerations for conducting healthcare market research in the Gulf

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Patient Centricity: Turning Rhetoric into Reality

Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST

Making sense of Nutraceuticals in China

Published in eyeforpharma February 2017 by Marc Yates

Research Partnership has been ranked in the Pharma Times Pharma Fast 50

Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research...

Women’s health in emerging markets

Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and...

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide.